Scholars Central

Conference abstractPublished 26 Apr 2018

The glycosylation aspects of biosimilarity

Authors: Andras Guttman

SCIEX, USA

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Recent expiration of a number of protein therapeutics opened up the door for biosimilar development. Biosimilars are biologic medical products, which are similar but not identical copies of already authorized protein therapeutics. Critical Quality Attributes (CQA) such as post translational modifications of recombinant biotherapeutics, are important for clinical efficacy and safety of both the innovative biologics and their biosimilar counterparts. The first part of this presentation summarizes biosimilarity CQAs, considering the regulatory guidelines and the statistical aspects (e.g., biosimilarity index). The second part discusses glycosylation as one of the important attributes of biosimilarity in detail. Finally, the term of glycosimilarity index is introduced, based on the averaged biosimilarity criterion.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Bioanalysis & Biomedicine.

All its articles

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Bioanalysis & Biomedicine
  • BylineArticles whose byline prints “Andras Guttman”